An Study of Efficacy and Safety of Clevudine

• Patients are between 18 and 65, inclusive.
• All the male and female reproductive-aged subjects should use reliable and appropriate contraceptive method from the entrance of screening to at least 3 months within the end of study.
• Hepatitis B virus Early Antigen (HBeAg) positive patient with HBV DNA >1 x 105 copies/ml, HBeAg negative patient with HBV DNA >1 x 104 copies/ml within 30 days of baseline.
• Absolute neutrophil count > 1500 /mm3.
• Alpha fetoprotein within normal laboratory limit at screening.
• Normal electrocardiogram (ECG) or clinically non-significant changes at screening.
• Able to participate and willing to give written informed consent before starting therapy.
• Able and willing to comply with study assessments and restrictions.
• Normal renal function to take Adefovir without any dose modifications; Creatinine clearance must be >50 ml/min (based on the Cockcroft-Gault equation.

Exclusion criteria

• Subjects coinfected with human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV) or hepatitis E virus
• Patients previously or currently treated with approved and investigational nucleosides (e.g.: lamivudine, adefovir. entecavir, lobucavir, famciclovir, tenofovir, telbivudine) for any duration.
• Other chronic hepatic disease. e.g. chronic alcoholism. Wilson's disease.
• Poorly controlled type I or type 2 diabetes mellitus
• Donation or loss more than 400 ml blood within 60 days of baseline.
• Known serious allergies to nucleoside/nucleotide analogs.
• Subjects who are pregnant, nursing, or unwilling to use appropriate form of contraception.